by | Jan 13, 2022 | Uncategorized
Source: Cure Today articles Although patients with multiple myeloma may be concerned that a reduction in treatment dose may be less effective, an expert from The Tisch Cancer Institute stresses that it may be more beneficial. Read More
by | Jan 5, 2022 | Uncategorized
Source: Cure Today articles An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care...
by | Jan 4, 2022 | Uncategorized
Source: Cure Today articles From an overview of the disease to notable deaths and clinicians who go the extra mile, here is a list of CURE®’s most-read myeloma articles from 2021. Read More
by | Dec 21, 2021 | Uncategorized
Source: Cure Today articles A certified oncology nurse and board-certified adult nurse practitioner explained how the recent FDA approval of Darzalex Faspro, Kyprolis and dexamethasone may allow patients with relapsed/refractory multiple myeloma to switch treatments...
by | Dec 15, 2021 | Uncategorized
Source: Cure Today articles Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial. Read More
by | Dec 15, 2021 | Uncategorized
Source: Cure Today articles Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma. Read More
